FGFR2 and neoplasm: For instance, the Japanese GI-SCREEN and GOZILA molecular profiling studies revealed that FGFR2 amplification in patients with advanced GC was more frequently detected by ctDNA sequencing (7.7% of cases) compared to by tissue analysis alone (2.6–4.4% of cases), and notably 2 patients with FGFR2 amplification detected by ctDNA sequencing after tumour progression but not by tissue analysis of the pre-treatment sample had responses to FGFR inhibitors [97].